Trials / Completed
CompletedNCT03282591
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Vyne Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5 mg Serlopitant Tablets | Serlopitant Tablets |
| DRUG | Matching Placebo Tablets | Placebo Tablets |
Timeline
- Start date
- 2017-10-03
- Primary completion
- 2018-08-15
- Completion
- 2018-09-06
- First posted
- 2017-09-14
- Last updated
- 2021-05-20
- Results posted
- 2019-10-22
Locations
39 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03282591. Inclusion in this directory is not an endorsement.